Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Apr 7;32(4):204–209. doi: 10.1002/clc.20321

Markers of Thrombosis and Hemostasis in Acute Coronary Syndromes: Relationship to Increased Heart Rate and Reduced Heart‐Rate Variability

Ali Hamaad 1, Michael D Sosin 1, Andrew D Blann 1, Gregory Y H Lip 1, Robert J MacFadyen 1,✉
PMCID: PMC6653381  PMID: 19353696

Abstract

Background

Acute coronary syndromes (ACS) are characterized by abnormal heart‐rate variability (HRV) and biomarkers of endothelial damage and thrombosis.

Hypothesis

We hypothesized an association between these factors in patients with ACS.

Methods

We studied 99 patients with ACS measuring HRV and plasma markers of endothelial damage/dysfunction (von Willebrand factor, vWF) and thrombosis/hemostasis (soluble P‐selectin (s‐Psel); CD40‐ligand (CD40‐L); d‐dimer). HRV and plasma indices were compared to age‐ and gender‐matched controls. Measures were repeated at 4 months in a subset. vWF, s‐Psel and d‐Dimer levels were raised compared to control.

Results

HRV indices were reduced (mean RR, SDNN, SDNNi, RMSSD, Triangular index, LF and HF). There were weak correlations between mean RR and s‐Psel (R = − 0.234, p = 0.023) and d‐dimer (R = − 0.219, p = 0.041). At 4‐month follow‐up, significant correlations were between mean RR and CD40L (R = − 0.414, p = 0.008) and d‐dimer (R = − 0.363, p = 0.012). On multivariate logistic regression analysis statin use (p = 0.046) was the only independent predictor of acute s‐Psel levels. Age (p = 0.004) and mean RR interval (p = 0.01) were independent predictors of d‐dimer levels at follow‐up.

Conclusions

Abnormal HRV is associated with markers of hemostasis and thrombosis in ACS, and present both in the acute and rehabilitation phases. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (489.6 KB).

References

  • 1. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology . Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996; 93(5): 1043–1065. [PubMed] [Google Scholar]
  • 2. Tsuji H, Vendetti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham Heart Study. Circulation. 1994; 90: 878–883. [DOI] [PubMed] [Google Scholar]
  • 3. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ, The Multicenter Post‐Infarction Research Group . Decreased heart rate variability and its association with increased mortality after myocardial infarction. Am J Cardiol. 1987; 59: 256–262. [DOI] [PubMed] [Google Scholar]
  • 4. Lombardi F, Sandrone G, Pernpruner S, et al. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol. 1987; 60: 1239–1245. [DOI] [PubMed] [Google Scholar]
  • 5. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984; 226: 180–182. [DOI] [PubMed] [Google Scholar]
  • 6. Sajadieh A, Nieslen OW, Rasmussen V, et al. Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle‐aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004; 25: 363–370. [DOI] [PubMed] [Google Scholar]
  • 7. Cucuiano MP, Cristea A, Roman S, et al. Comparative behaviour of the components of the factor VIII complex in acute myocardial infarction. Thromb Res. 1983; 30: 487–497. [DOI] [PubMed] [Google Scholar]
  • 8. Hillis GS, Terregino C, Taggart P, et al. Elevated soluble P‐selectin levels are associated with an increased risk of adverse events in patients with presumed myocardial ischaemia. Am Heart J. 2002; 142: 235–241. [DOI] [PubMed] [Google Scholar]
  • 9. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40‐ligand in acute coronary syndromes. N Engl J Med. 2003; 348: 1104–1111. [DOI] [PubMed] [Google Scholar]
  • 10. Lew AS, Berberian L, Cercek B, et al. Elevated serum d‐dimer: a degradation product of cross‐linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. J Am Coll Cardiol. 1986; 7: 1320–1324. [DOI] [PubMed] [Google Scholar]
  • 11. O'Brien JR. Some effects of adrenaline and anti‐adrenaline on platelets in vitro and vivo. Nature. 1963; 200: 763–764. [DOI] [PubMed] [Google Scholar]
  • 12. Lalau Keraly C, Kinlogh‐Rathbone RL, Packham MA, Suzuki H, Mustard JF. Conditions affecting the response of human platelets to epinephrine. Thromb Haemost. 1988; 60: 209–216. [PubMed] [Google Scholar]
  • 13. Larsson PT, Hjemdahl P, Olsson G, Angelin B, Hornstra G. Platelet aggregability in humans: contrasting in‐vivo and in‐vitro findings during sympathoadrenal activation and relationship to serum lipids. Eur J Clin Invest. 1990; 20: 398–405. [DOI] [PubMed] [Google Scholar]
  • 14. Siess W, Lorenz R, Roth P, Weber PC. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation. 1982; 66: 44–48. [DOI] [PubMed] [Google Scholar]
  • 15. Arkel YS, Haft JI, Kreutner W, Sherwood J, Williams R. Alteration in second phase platelet aggregation associated with an emotionally stressful activity. Thromb Haemost. 1977; 38: 552–561. [PubMed] [Google Scholar]
  • 16. Mehta J, Mehta P, Pepine CJ. Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease: role of tachycardia, stress and propranolol. Circulation. 1978; 58: 881–886. [DOI] [PubMed] [Google Scholar]
  • 17. Mikhailidis DP, Barradas MA, Mier A, et al. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology. 1987; 38: 36–45. [DOI] [PubMed] [Google Scholar]
  • 18. Ogston D, McDonald GA, Fullerton HW. The influence of anxiety in tests of blood coagulability and fibrinolytic activity. Lancet. 1962; 2: 521–523. [DOI] [PubMed] [Google Scholar]
  • 19. Cash JD, Allan AGE. Effect of mental stress on the fibrinolytic reactivity to exercise. Br Med J. 1967; 2: 545–548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Cash JD, Woodfield DG, Allan AG. Adrenergic mechanisms in the systemic plasminogen activator response to epinephrine in man. Br J Haematol. 1970; 18: 487–494. [DOI] [PubMed] [Google Scholar]
  • 21. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36: 959–969. [DOI] [PubMed] [Google Scholar]
  • 22. Kayikcioglu M, Can L, Mete‐Erdem N, et al. Soluble P‐selectin and the success of thrombolysis in acute myocardial infarction. Int J Cardiol. 2001; 79: 223–229. [DOI] [PubMed] [Google Scholar]
  • 23. Mulvihill N, Foley JB, Ghaisas N, et al. Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. Am J Cardiol. 1999; 83: 1265–1267. [DOI] [PubMed] [Google Scholar]
  • 24. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40‐ligand/CD154 on platelets. Heart. 2001; 86: 649–655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin‐6 levels in patients with acute myocardial infarction. Am Heart J. 1993; 126: 1299–1304. [DOI] [PubMed] [Google Scholar]
  • 26. Liuozzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C‐reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331: 417–424. [DOI] [PubMed] [Google Scholar]
  • 27. Casolo GC, Strode P, Sigorini C, et al. Heart rate variability during the acute phase of myocardial infarction. Circulation. 1992; 85(6): 2073–2079. [DOI] [PubMed] [Google Scholar]
  • 28. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC, Scneider WJ. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol. 1991; 18: 1643–1649. [DOI] [PubMed] [Google Scholar]
  • 29. Hamaad A, Sosin M, Blann AD, et al. Markers of inflammation in acute coronary syndromes: associations with increased heart rate and reductions in heart rate variability. Clin Cardiol. 2005; 28: 570–576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Bacon SL, Ring C, Hee FL, et al. Haemodynamic, haemostatic, and endothelial reactions to psychological and physical stress in coronary artery disease patients. Biol Psychol. 2006; 71: 162–170. [DOI] [PubMed] [Google Scholar]
  • 31. Lee KW, Blann AD, Ingram J, Jolly K, Lip GYH. Incremental shuttle walking is associated with activation of haemostatic and haemorrheological markers in patients with coronary artery disease: the Birmingham rehabilitation uptake maximisation study (BRUM). Heart. 2005; 91: 1413–1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999; 100: 614–620. [DOI] [PubMed] [Google Scholar]
  • 33. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK‐HEART). Circulation. 1998; 98: 1510–1516. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES